# Wakayama Medical University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/wakayama-medical-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 67.4 |
| Citations | 1,117,738 |
| City | Wakayama |
| Country | JP |
| Description | Wakayama Medical University is a research organisation in Wakayama, JP. OpenAlex records 14,072 works and 1,117,738 citations for it. 2,856 researchers list it as their most recent affiliation. |
| Homepage | http://www.wakayama-med.ac.jp/english/index.html |
| OpenAlex ID | https://openalex.org/I190805021 |
| Researchers | 2,856 |
| ROR ID | https://ror.org/005qv5373 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q4707175 |
| Works | 14,072 |

## University papers

Showing 12 of 62.

- [Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses](https://scholariq.org/papers/differential-roles-of-mda5-and-rig-i-helicases-in-the-recognition-of-rna-viruses/)
- [Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Essential involvement of interleukin-8 (IL-8) in acute inflammation](https://scholariq.org/papers/essential-involvement-of-interleukin-8-il-8-in-acute-inflammation/)
- [Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6](https://scholariq.org/papers/clinical-activity-of-afatinib-in-patients-with-advanced-non-small-cell-lung/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis](https://scholariq.org/papers/blocking-tnf-in-mice-reduces-colorectal-carcinogenesis-associated-with-chronic/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer](https://scholariq.org/papers/whole-genome-mutational-landscape-and-characterization-of-noncoding-and/)
- [Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-durvalumab-for-resectable-non-small-cell-lung-cancer/)
- [Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney](https://scholariq.org/papers/calorie-restriction-enhances-cell-adaptation-to-hypoxia-through-sirt1-dependent/)

## University researchers

- [Nobuyuki Yamamoto](https://scholariq.org/researchers/nobuyuki-yamamoto/)
- [Toshikazu Kondo](https://scholariq.org/researchers/toshikazu-kondo/)
- [Hiroaki Akamatsu](https://scholariq.org/researchers/hiroaki-akamatsu/)
- [Shin‐ichi Araki](https://scholariq.org/researchers/shin-ichi-araki/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Spine and Intervertebral Disc Pathology](https://scholariq.org/topics/spine-and-intervertebral-disc-pathology/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.